Montes Archimedes Acquisition (ROIV)
(Delayed Data from NSDQ)
$10.83 USD
-0.15 (-1.37%)
Updated May 28, 2024 04:00 PM ET
After-Market: $10.82 -0.01 (-0.09%) 7:58 PM ET
4-Sell of 5 4
F Value F Growth B Momentum F VGM
Brokerage Reports
Roivant Sciences Ltd. [ROIV]
Reports for Purchase
Showing records 21 - 27 ( 27 total )
Company: Roivant Sciences Ltd.
Industry: Unclassified
Vtama''s Profile Should Drive Adoption; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Roivant Sciences Ltd.
Industry: Unclassified
Roivant Enters Patent Infringement Litigation Against Moderna Regarding LNPs; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Roivant Sciences Ltd.
Industry: Unclassified
On Track for Tapi Launch in Calendar 2Q22 and Details of Hemavant Revealed; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Roivant Sciences Ltd.
Industry: Unclassified
Rx for Portfolios, Part 3: Commercial Launches Worth Keeping an Eye On
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Roivant Sciences Ltd.
Industry: Unclassified
Santa Comes Early With a Gift to Roivant as Appeals Court Rules in Favor of Arbutus and Roivant?s SNALP Patent; Reit Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Roivant Sciences Ltd.
Industry: Unclassified
Lots to Look Forward to for Tapi, ?1401, ?1801, and the Pipe in Catalyst-Rich 2022
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Roivant Sciences Ltd.
Industry: Unclassified
Doc Survey Suggest Strong Uptake for Tapinarof, While Other Vants Offer Upside; Initiate With Buy and $14 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D